Key insights
- The article discusses ReposiTrak (TRAK), a SaaS company providing food safety compliance software. The author believes TRAK is undervalued due to the FDA's FSMA Rule 204, which mandates end-to-end traceability in the food industry. This regulation creates a network effect, as retailers require suppliers to use compliant platforms like ReposiTrak. The author calculates owner earnings per share at $0.49 and suggests a 20x multiple, implying significant upside.
I've been digging into ReposiTrak (TRAK) — a $140M market cap SaaS company out of Utah that nobody talks about. I think it's genuinely mispriced and wanted to share my work.
What they do
ReposiTrak is the digital plumbing behind food safety compliance. If you're a major grocery chain, you can't afford to sell tainted spinach. TRAK provides the platform that traces every product back to where it was grown, processed, and shipped. Completely hardware-free — it's pure software.
The key differentiator is their 500+ error-correction algorithms. They don't just pass data around; they actively detect and fix bad supplier data. That matters because garbage-in-garbage-out kills traceability.
Why now — the FDA catalyst
The FDA's FSMA Rule 204 is forcing the entire food industry to implement end-to-end traceability. This isn't optional. Retailers are scrambling, and they're mandating their suppliers get on a compliant platform. When Walmart tells its 10,000 suppliers "get on ReposiTrak or we drop you," those suppliers don't have much choice.
This creates a brutal network effect. Once a retailer's supply chain is wired into TRAK, switching costs are massive. It's toll-bridge economics — you pay to cross, or your product doesn't reach the shelf.
The numbers (Owner Earnings, not GAAP nonsense)
I use owner earnings (Buffett-style) because I want to know how much cash I can actually pull out of this business:
| | | |---|---| | Operating Cash Flow | $6.87M | | Less: Stock-Based Comp | -$0.46M | | WC Add-back (timing noise, asset-light SaaS) | +$2.76M | | Less: Maintenance CapEx (5yr avg, 1.34% of rev) | -$0.30M | | Owner Earnings | $8.87M | | OE Per Share (18.28M diluted) | $0.49 |
Quality metrics:
- ROIC: 14.78% - 5-year OE CAGR: 30.92% - ~99% recurring revenue - Net cash: $28.31M, debt: $0.40M (basically zero) - Buybacks: $4.35M TTM — management eating their own cooking
Valuation
I apply a 20x multiple to owner earnings. That's reasonable for a high-ROIC, asset-light SaaS with recurring revenue and a regulatory tailwind. Add back $1.55/share in net cash:
- IV = ($0.49 x 20) + $1.55 = $11.35/share - Current price: $7.55 - Margin of safety: 33.5%
The market is pricing this at 12.37x — a stagnant-survivor multiple for a business growing OE at 30%+ annually. That disconnect is the opportunity.
Risks
- Cybersecurity breach — This is the material risk. If a hack shatters retailer trust, the network effect reverses. The entire value proposition is trust-based. 2. Onboarding bottleneck — As FSMA deadlines hit, thousands of suppliers need to onboard simultaneously. Execution risk is real but temporary — the platform is built to scale.
My verdict: BUY
High-ROIC toll bridge, 99% recurring revenue, FDA tailwind forcing adoption, fortress balance sheet, management buying back stock aggressively — and the market is letting you buy it at a 33% discount because it's too small for institutions to care about.
Buy zone: below $8.51. Current price is well inside.
I also made a video walkthrough of the full analysis if you prefer that format: https://youtu.be/FqY4aIvsKOQ
Disclosure: I hold a position in TRAK. This is not financial advice — do your own research.